Viatris Q2 Earnings Preview: Analyst Expectations

Viatris is set to announce its Q2 earnings on Thursday. Wall Street expects EPS of $0.56, down 19%, and revenue of $3.46 billion, down 9%.

Viatris Inc. (VTRS), a global healthcare company, is scheduled to release its second-quarter 2025 earnings on Thursday, July 7, 2025, before the market opens. Wall Street analysts are expecting the company to report earnings per share (EPS) of $0.56, a 19% decrease from the same period last year, and revenue of $3.46 billion, a 9% decline year over year.

The company operates under four geographic segments: Developed Markets, Emerging Markets, Japan, Australia, and New Zealand (JANZ), and Greater China. Growth in the Developed Markets segment, driven by brands like Creon, Brufen, and the Thrombosis portfolio, has likely boosted sales despite a decline in generics. Sales from Emerging Markets have shown resilience due to growth in certain Latin American countries and the Middle East and North America regions. The JANZ segment, however, has been negatively impacted by government-driven price regulations and reimbursement changes. Greater China, on the other hand, has seen an increase in sales due to the company's diversified model across e-commerce, retail, and private hospitals.

Viatris' revenue is also segmented into brands and generics. The brand business, which comprises the majority of the portfolio, has benefited from the expansion of its cardiovascular portfolio in certain Latin American countries and strong growth in Europe and Greater China. Operating expenses might have risen during the quarter due to SG&A investments in new product launches and progress in key R&D programs.

The company's share price has been volatile, losing 29.3% in the past year compared to the industry's decline of 8.4%. Viatris has a mixed earnings surprise history, beating estimates in three of the trailing four quarters and missing in the remaining one, with an average surprise of 2.14%. The latest earnings beat was 2.04% in the last reported quarter.

Analysts are expecting Viatris' revenue to decline 9.5% year over year to $3.44 billion and adjusted earnings to come in at $0.56 per share. The company has missed Wall Street's revenue estimates six times over the last two years. Peers in the pharmaceuticals segment have reported mixed results, with some showing revenue growth and others experiencing declines.

The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some pharmaceutical stocks have shown solid performance, the group has generally underperformed, with share prices down 3.1% on average over the last month. Viatris is down 2.3% during the same time and is heading into earnings with an average analyst price target of $11.14.

References

[1] https://finance.yahoo.com/news/viatris-poised-report-q2-earnings-180700520.html
[2] https://finance.yahoo.com/news/viatris-vtrs-reports-earnings-tomorrow-031001240.html
[3] https://markets.financialcontent.com/wral/article/stockstory-2025-8-6-viatris-vtrs-reports-earnings-tomorrow-what-to-expect